Research Article

Can the de Ritis Ratio (AST/ALT) Be Used to Predict Colon Cancer Stages?

Volume: 7 Number: 2 August 7, 2023
EN TR

Can the de Ritis Ratio (AST/ALT) Be Used to Predict Colon Cancer Stages?

Abstract

Purpose: The De Ritis ratio (Aspartate transaminase/alanine transaminase) is a critical prognostic factor for some kinds of malignant tumors. Nevertheless, the De Ritis ratio’s prognostic value in preoperative colon cancer staging is unclear. The purpose of this research was to determine the De Ritis ratio and its prognostic significance for colon cancer. Materials and Methods: The clinicopathological data of 271 individuals with malign colon cancer were analyzed retrospectively at a single center from January 2010 to January 2018. The relationship between the De Ritis coefficient and clinicopathological findings in patients was evaluated before treatment. To compare the groups, the Mann-Whitney U test and the Kruskal Wallis test were performed. Results: The results indicated that there were no statistically significant differences between the groups in terms of pre-treatment De Ritis ratio assessment as a staging, localization, tumor diameter, lymph node metastasis, age, and overall survival. However, differences in T staging between groups of male participants were shown to be statistically significant. Conclusions: The De Ritis ratio evaluation before treatment was not found as an independent variable prognostic factor for the diagnosis and staging of colon cancer. However, future studies may demonstrate the significance of the De Ritis ratio with more participants.

Keywords

References

  1. 1. Chen SL, Li JP, Li LF, Zeng T, He X. Elevated Preoperative Serum Alanine Aminotransferase / Aspartate Aminotransferase (ALT/AST) Ratio Is Associated with Better Prognosis in Patients Un-dergoing Curative Treatment for Gastric Adeno-carcinoma. Int J Mol Sci. 2016;17(6):911.
  2. 2. Bezan A, Mrsic E, Krieger D, et al. The Pre-operative AST/ALT (De Ritis) Ratio Represents a Poor Prognostic Factor in a Cohort of Patients with Nonmetastatic Renal Cell Carcinoma. J Urol. 2015;194(1):30-35.
  3. 3. Varol U, Kaya E, Oflazoglu U, et al. Prognostic role of De Ritis and basal neutrophil to lympho-cyte ratio in patients with advanced stage pancre-atic cancer [IzmirOncologyGroup (IZOG) Study]. J BUON. 2020;25(2):1063-1069.
  4. 4. Knittelfelder O, Delago D, Jakse G, et al. The AST/ALT (De Ritis) Ratio Predicts Survival in Patients with Oral and Oropharyngeal Can-cer. Diagnostics (Basel). 2020;10(11):973.
  5. 5. Wu J, Chen L, Wang Y, Tan W, Huang Z. Prog-nostic value of aspartate transaminase to alanine transaminase (De Ritis) ratio in solid tumors: a pooled analysis of 9,400 patients. Onco Targets Ther. 2019;12:5201-5213.
  6. 6. Liu L, Wang W, Zhang Y, et al. Declined Pre-operative Aspartate Aminotransferase to Neutro-phil Ratio Index Predicts Poor Prognosis in Pa-tients with Intrahepatic Cholangiocarcinoma after Hepatectomy. Cancer Res Treat. 2018;50(2):538-550.
  7. 7. Mori K, Janisch F, Mostafaei H, et al. Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterec-tomy. Urol Oncol. 2020;38(6):601.e17-601.e24.
  8. 8. Ha YS, Kim SW, Chun SY, et al. Association be-tween De Ritis ratio (aspartateaminotransferase / alanineaminotransferase) and oncological out-comes in bladder cancer patients after radical cystectomy. BMC Urol. 2019;19(1):10.

Details

Primary Language

English

Subjects

Clinical Sciences, Clinical Sciences (Other)

Journal Section

Research Article

Early Pub Date

July 5, 2023

Publication Date

August 7, 2023

Submission Date

February 24, 2022

Acceptance Date

October 18, 2022

Published in Issue

Year 2023 Volume: 7 Number: 2

APA
Altıner, S., Cebeci, E., Sucu, B. B., Çöl, M., Ergüder, E., Ünal, Y., Tuncal, S., & Pekcici, M. R. (2023). Can the de Ritis Ratio (AST/ALT) Be Used to Predict Colon Cancer Stages? Ahi Evran Medical Journal, 7(2), 140-144. https://doi.org/10.46332/aemj.1077653
AMA
1.Altıner S, Cebeci E, Sucu BB, et al. Can the de Ritis Ratio (AST/ALT) Be Used to Predict Colon Cancer Stages? Ahi Evran Med J. 2023;7(2):140-144. doi:10.46332/aemj.1077653
Chicago
Altıner, Saygın, Enes Cebeci, Bedri Burak Sucu, et al. 2023. “Can the de Ritis Ratio (AST ALT) Be Used to Predict Colon Cancer Stages?”. Ahi Evran Medical Journal 7 (2): 140-44. https://doi.org/10.46332/aemj.1077653.
EndNote
Altıner S, Cebeci E, Sucu BB, Çöl M, Ergüder E, Ünal Y, Tuncal S, Pekcici MR (August 1, 2023) Can the de Ritis Ratio (AST/ALT) Be Used to Predict Colon Cancer Stages? Ahi Evran Medical Journal 7 2 140–144.
IEEE
[1]S. Altıner et al., “Can the de Ritis Ratio (AST/ALT) Be Used to Predict Colon Cancer Stages?”, Ahi Evran Med J, vol. 7, no. 2, pp. 140–144, Aug. 2023, doi: 10.46332/aemj.1077653.
ISNAD
Altıner, Saygın - Cebeci, Enes - Sucu, Bedri Burak - Çöl, Mert - Ergüder, Ender - Ünal, Yılmaz - Tuncal, Salih - Pekcici, Mevlüt Recep. “Can the de Ritis Ratio (AST ALT) Be Used to Predict Colon Cancer Stages?”. Ahi Evran Medical Journal 7/2 (August 1, 2023): 140-144. https://doi.org/10.46332/aemj.1077653.
JAMA
1.Altıner S, Cebeci E, Sucu BB, Çöl M, Ergüder E, Ünal Y, Tuncal S, Pekcici MR. Can the de Ritis Ratio (AST/ALT) Be Used to Predict Colon Cancer Stages? Ahi Evran Med J. 2023;7:140–144.
MLA
Altıner, Saygın, et al. “Can the de Ritis Ratio (AST ALT) Be Used to Predict Colon Cancer Stages?”. Ahi Evran Medical Journal, vol. 7, no. 2, Aug. 2023, pp. 140-4, doi:10.46332/aemj.1077653.
Vancouver
1.Saygın Altıner, Enes Cebeci, Bedri Burak Sucu, Mert Çöl, Ender Ergüder, Yılmaz Ünal, Salih Tuncal, Mevlüt Recep Pekcici. Can the de Ritis Ratio (AST/ALT) Be Used to Predict Colon Cancer Stages? Ahi Evran Med J. 2023 Aug. 1;7(2):140-4. doi:10.46332/aemj.1077653

Ahi Evran Medical Journal  is indexed in ULAKBIM TR Index, Turkish Medline, DOAJ, Index Copernicus, EBSCO and Turkey Citation Index. Ahi Evran Medical Journal is periodical scientific publication. Can not be cited without reference. Responsibility of the articles belong to the authors.

    Creative Commons Lisansı

This journal is licensed under the Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı.